earnings
confidence high
sentiment positive
materiality 0.70
NeurAxis Q3 revenue up 40% to $667K; operating loss narrows 45%; secures $5M investment
Neuraxis, INC
2024-Q3 EPS reported
-$1.01
revenue$1,924,760
- Revenue $667K, +40% YoY; unit sales +50%.
- Operating loss $1.7M, improved 45% from $3.0M; net loss $1.8M, improved 80%.
- Expanded insurance coverage to ~35M lives (from 4.5M); new FDA clearance for IB-Stim ages 8-21.
- Received CPT Category I code for PENFS effective Jan 1, 2026.
- Entered $5.0M investment agreement (closing mid-Nov), replacing prior $3.2M commitment; cash on hand $261K.